key: cord-1015371-0rxqt3kx
authors: Nanes, Benjamin A.
title: Androgenetic alopecia in COVID-19: Compared to what?
date: 2020-07-29
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.1031
sha: 797e2335c25e5419e86f9a0be7875f8790365fca
doc_id: 1015371
cord_uid: 0rxqt3kx

nan

In a timely study certain to attract considerable attention, Wambier et al. propose an association between androgenetic alopecia (AGA) and severe manifestations of COVID-19. 1 In a cohort of hospitalized COVID-19 patients, they find AGA prevalence of 79% in males and 42% in females, citing other literature to argue these rates exceed expectation. Unfortunately, in the absence of additional clarification, the literature cited does not appear to support this claim. Rather, it suggests these rates are unremarkable.

For males, the authors cite AGA prevalence in "age matched males in a similar Caucasian population," indirectly referencing two cross-sectional studies. 2, 3 How this data was aggregated and "age matched" to the COVID-19 cohort is not described. One of these studies reports age-stratified AGA rates in several categories. 2 matching the 79% prevalence in the COVID-19 cohort with median age 62.5. The second study reports even higher AGA rates, with HNS ≥ II in 31 of 32 (97%) and HNS ≥ IV in 27 of 32 (84%) of men age 60-69. 3 At least based on these data, AGA prevalence in the COVID-19 cohort hardly seems unexpected.

For females, Wambier et al. cite a review 4 to claim that the "highest AGA prevalence reported was 38%." This figure appears come from a cross-sectional study of 377 patients age 18-99, with 38% AGA prevalence in age ≥ 70. 5 The same review 4 also cites another cross-sectional study which found 67 of 125 (54%) of females age 70-79 had "cosmetically significant" AGA. 6 Since the median age in the female COVID-19 cohort is 71, these groups are relatively age-appropriate comparisons. While exact comparison between different definitions of AGA is not possible, 42% AGA prevalence reported by Wambier et al. is likely consistent with 38% or 54% prevalence reported by these prior studies.

For both males and females, the literature cited by Wambier et al. suggests that the prevalence of AGA in hospitalized COVID-19 patients is close to the expected rate. While male sex and older age may be risk factors for COVID-19 mortality, the hypothesis that AGA may be independently associated with severe manifestations of COVID-19 remains a matter of conjecture. Given the unprecedented public interest in COVID-19 research in the context of an ongoing pandemic, any purported association requires more cautious assessment of the underlying data.

Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients -the "Gabrin sign

Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors

Patterned loss of hair in man; types and incidence

Female Pattern Hair Loss: a clinical and pathophysiological review

Hair density, hair diameter and the prevalence of female pattern hair loss

Prevalence of male and female pattern hair loss in Maryborough